Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 4/2019

01-04-2019 | Biomarkers | Review Article

The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis

Authors: Peng Wang, LiangLiang Xu, Lian Li, ShengSheng Ren, JianWei Tang, Ming Zhang, MingQing Xu

Published in: European Archives of Oto-Rhino-Laryngology | Issue 4/2019

Login to get access

Abstract

Background

The prognostic value of microRNA-375 (miR-375) expression in squamous cell carcinoma (SCC) had been reported in the previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic significance of miR-375 expression in SCC based on all eligible evidences.

Methods

Relevant studies were identified by searching PubMed, Embace, Medline, Cochrane Library, and China Biology Medicine disk. Survival outcome including overall survival (OS) and other survival outcomes were used as the primary endpoint to evaluate the prognostic outcome of patients with SCC. All statistical analyses were performed in RevMan software version 5.3 and STATA software version 14.1. Furthermore, the quality of included studies was assessed by The Newcastle–Ottawa Scale.

Results

In total, 13 studies, including 1340 patients, met the inclusion criteria for our meta-analysis. The pooled analysis results indicated that downregulation of miR-375 significantly predicted poor OS (HR 1.58, 95% CI 1.34–1.88, P < 0.001). Downregulated miR-375 was also correlated with the other survival outcomes. Subgroup analysis based on tumor type found that lower expression of miR-375 was significantly related with poor OS in patients with esophageal squamous cell carcinoma (ESCC) (HR 1.58, 95% CI 1.29–1.94, P < 0.001) and head and neck squamous cell carcinoma (HNSCC) (HR 1.59, 95% CI 1.16–2.18, P = 0.004).

Conclusions

This meta-analysis demonstrated that the downexpression of miR-375 was significantly correlated with poor OS in patients with SCCs and indicated the potential clinical use of miR-375 as a molecular biomarker, particularly in assessing prognosis for patients with ESCC and HNSCC.
Literature
1.
Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRef
2.
3.
Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917CrossRef
4.
5.
Tran GD et al (2005) Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 113(3):456–463CrossRefPubMed
6.
Ruol A et al (2009) Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg 144(3):247–254 (discussion 254) CrossRefPubMed
7.
Srivastava VK et al (2014) Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev 15(7):3261–3265CrossRefPubMed
8.
9.
Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576–582CrossRef
10.
Gonzalez Ferreira JA et al (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother 20(5):328–339CrossRefPubMedPubMedCentral
11.
Komatsu S et al (2012) Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 12(Suppl 1):S53–S59CrossRefPubMed
12.
Costello E, Greenhalf W, Neoptolemos JP (2012) New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9(8):435–444CrossRefPubMed
13.
Du Y et al (2013) Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Cancer Biother Radiopharm 28(5):361–369CrossRefPubMed
14.
Gao W et al (2018) Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol Ther 27:1–2
15.
Meng L et al (2018) Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins. Cell Death Dis 9(11):1057CrossRefPubMedPubMedCentral
16.
Lamperska KM et al (2016) Unpredictable changes of selected miRNA in expression profile of HNSCC. Cancer Biomark 16(1):55–64CrossRefPubMed
17.
Marioni G et al (2016) miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. J Clin Pathol 69(5):415–421CrossRefPubMed
18.
Zhao H et al (2018) MiR-543 promotes migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells by targeting phospholipase A2 group IVA. Cell Physiol Biochem 48(4):1595–1604CrossRefPubMed
19.
20.
Hui AB et al (2011) Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 17(24):7539–7550CrossRefPubMed
21.
Harris T et al (2012) Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180(3):917–928CrossRefPubMedPubMedCentral
22.
Kinoshita T et al (2012) The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet 57(9):556–563CrossRefPubMed
23.
Yan JW, Lin JS, He XX (2014) The emerging role of miR-375 in cancer. Int J Cancer 135(5):1011–1018CrossRefPubMed
24.
He XX et al (2012) MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 31(28):3357–3369CrossRefPubMed
25.
Ding L et al (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784–793CrossRefPubMed
26.
Mathe EA et al (2009) MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15(19):6192–6200CrossRefPubMedPubMedCentral
27.
Chang C et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208CrossRefPubMed
28.
Li X, Lin R, Li J (2011) Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 56(10):2849–2856CrossRefPubMed
29.
30.
Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRef
31.
Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed
32.
Zhang B et al (2017) MicroRNA-375 inhibits growth and enhances radiosensitivity in oral squamous cell carcinoma by targeting insulin like growth factor 1 receptor. Cell Physiol Biochem 42(5):2105–2117CrossRefPubMed
33.
He Y et al (2017) Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China. Clin Exp Metastasis 34(1):73–84CrossRefPubMed
34.
Hudcova K et al (2016) Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. Tumour Biol 37(9):12627–12633CrossRefPubMed
35.
Lv H et al (2016) Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication. Am J Transl Res 8(7):3288–3298PubMedPubMedCentral
36.
Li BX et al (2015) Circulating microRNAs in esophageal squamous cell carcinoma: association with locoregional staging and survival. Int J Clin Exp Med 8(5):7241–7250PubMedPubMedCentral
37.
Winther M et al (2015) Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncol 54(9):1582–1591CrossRefPubMed
38.
Hu A et al (2014) miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res 6(5):604–613PubMedPubMedCentral
39.
Jia L et al (2015) miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncol Rep 33(4):2061–2071CrossRefPubMed
40.
Wu C et al (2014) Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep 41(3):1257–1266CrossRef
41.
Li J et al (2013) Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 8(1):e53582CrossRefPubMedPubMedCentral
42.
Kong KL et al (2012) MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61(1):33–42CrossRefPubMed
43.
Lian S et al (2016) MicroRNA-375 functions as a tumor-suppressor gene in gastric cancer by targeting recepteur d’origine nantais. Int J Mol Sci 17(10):1–2CrossRef
44.
Cui F et al (2016) miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep 36(1):487–493CrossRefPubMed
45.
Osako Y et al (2016) Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol 49(6):2255–2264CrossRefPubMedPubMedCentral
46.
Jung HM, Benarroch Y, Chan EK (2015) Anti-cancer drugs reactivate tumor suppressor miR-375 expression in tongue cancer cells. J Cell Biochem 116(5):836–843CrossRefPubMed
47.
Jung HM et al (2013) Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA–mRNA interactions. Mol Biol Cell 24(11):1638–1648 (s1-7) CrossRefPubMedPubMedCentral
48.
49.
Elshafei A et al (2017) The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: an Egyptian study. Tumour Biol 39(6):1010428317705765CrossRefPubMed
Metadata
Title
The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis
Authors
Peng Wang
LiangLiang Xu
Lian Li
ShengSheng Ren
JianWei Tang
Ming Zhang
MingQing Xu
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Keyword
Biomarkers
Published in
European Archives of Oto-Rhino-Laryngology / Issue 4/2019
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-019-05325-8

Other articles of this Issue 4/2019

European Archives of Oto-Rhino-Laryngology 4/2019 Go to the issue

Rhinology

Otolaryngologists adhere to evidence-based guidelines for chronic rhinosinusitis

Laryngology

Microvascular density and hypoxia-inducible factor in intraepithelial vocal fold lesions

Otology

Comparative prognosis in patients with Ramsay-Hunt syndrome and Bell’s palsy

Rhinology

A prospective, non-randomized evaluation of a novel low energy radiofrequency treatment for nasal obstruction and snoring

Head & Neck

Correlation between the duration of locoregional control and survival in T1–T2 oropharyngeal cancer patients

Review

Syndromes that predispose to epistaxis